AI-driven insights

Monte Rosa Therapeutics’ AI platform, QuEEN™, has identified a vast array of human proteins targetable by molecular glue degraders (MGDs). Published in *Science*, this breakthrough significantly expands the universe of “undruggable” therapeutic targets, particularly for MGDs via cereblon. The company is integrating these AI-driven insights to accelerate its pipeline of novel MGD medicines, aiming to transform patient outcomes in oncology, immunology, and inflammation.